Drugmaker recalls samples of antiplatelet drugAstraZeneca voluntarily recalls professional samples of its antiplatelet agent. Here's what to do.
Use new data to inform unique patient group"Increasingly, urologists are faced with patients who cannot safely discontinue anticoagulation or antiplatelet medications, even in the face of an impending surgical procedure. This is a trend that is likely to continue into the foreseeable future," writes Brian R. Matlaga, MD, MPH.
FDA grants priority review to expand use of BrilintaThe FDA has granted Priority Review for ticagrelor (Brilinta, AstraZeneca) for patients with a history of heart attack.
FDA approves new administration option for BrilintaFDA has approved a new administration option for ticagrelor (Brilinta, AstraZeneca) in acute coronary syndrome patients.
Delay in filling clopidogrel prescription after coronary stent linked to adverse clinical outcomesA delay in filling the first prescription for clopidogrel after coronary stenting is associated with an increased risk of death and myocardial infarction (MI), according to a study published online May 28 in the Journal of the American Heart Association.